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Using a tailored health information
technology- driven intervention to improve
health literacy and medication adherence
in a Pakistani population with vascular
disease (Talking Rx) – study protocol for a
randomized controlled trial
Ayeesha Kamran Kamal1*, Abdul Muqeet2, Kashfa Farhat3, Wardah Khalid4, Anum Jamil3, Ambreen Gowani5,
Aliya Amin Muhammad6, Fabiha Zaidi6, Danyal Khan7, Touseef Elahi7, Shahrukh Sharif8, Sibtain Raz9, Taha Zafar9,
Syedah Saira Bokhari10, Nasir Rahman10, Fateh Ali Tipoo Sultan10, Saleem Sayani8 and Salim S. Virani11

Abstract
Background: Vascular disease, manifesting as myocardial infarction and stroke, is a major cause of morbidity and
mortality, especially in low- and middle-income countries. Current estimates are that only one in six patients have
good adherence to medications and very few have sufficient health literacy. Our aim is to explore the effectiveness
and acceptability of Prescription Interactive Voice Response (IVR) Talking Prescriptions (Talking Rx) and SMS reminders
in increasing medication adherence and health literacy in Pakistani patients with vascular disease.
Methods: This is a randomized, controlled, single center trial. Adult participants, with access to a cell phone and a
history of vascular disease, taking multiple risk-modifying medications (inclusive of anti-platelets and statins) will be
selected from cerebrovascular and cardiovascular clinics. They will be randomized in a 1:1 ratio via a block design to
the intervention or the control arm with both groups having access to a helpline number to address their queries in
addition to standard of care as per institutional guidelines. Participants in the intervention group will also have access
to Interactive Voice Response (IVR) technology tailored to their respective prescriptions in the native language (Urdu)
and will have the ability to hear information about their medication dosage, correct use, side effects, mechanism of
action and how and why they should use their medication, as many times as they like. Participants in the intervention
arm will also receive scheduled SMS messages reminding them to take their medications. The primary outcome
measure will be the comparison of the difference in adherence to anti-platelet and statin medication between baseline
and at 3-month follow-up in each group measured by the Morisky Medication Adherence Scale. To ascertain the
impact of our intervention on health literacy, we will also compare a local content-validated and modified version of
Test of Health Literacy in Adults (TOFHLA) between the intervention and the control arm.
We estimate that a sample size of 86 participants in each arm will be able to detect a difference of 1 point on the
MMAS with a power of 90 % and significance level of 5 %. Accounting for an attrition rate of 15 %, we plan to enroll
(Continued on next page)
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100 participants in each arm (total study population = 200). We hypothesize that a linguistically tailored health
IT intervention based on IVR and SMS will be associated with an improvement in adherence (to anti-platelet
and lipid-lowering medications) and an improvement in health literacy in Pakistani patients with vascular disease.
Discussion: This innovative study will provide early data for the feasibility of the use of IT based prescriptions in an
lower middle incorme country setting with limited numeracy and literacy skills.
Trial registration: Clinical Trials.gov: NCT02354040 − 2 February 2015
Keywords: Vascular disease, Medication adherence, Health literacy, Talking prescription, Information and
communication technology, Prevention, Non-communicable disease, Prevention, Lower and middle income countries

Background
Vascular risk, manifesting as myocardial infarction
(MI) and stroke, contributes to about 3.87 million premature deaths in the 30–69 year-old age group in
Pakistan [1]. In one of the largest case-control studies
of 15,152 cases of first MI and 14,820 controls, it was
shown that South Asian participants were relatively
young at the time of their first MI (mean age =
53 years) compared with participants from China or
Western Europe (mean age = 63 years) [2]. Nearly
10 % of these heart attacks in South Asian participants
occurred in individuals aged 40 or below. Similarly,
the reported lifetime prevalence of stroke symptoms is
19 % in urban Pakistan, which amounts to 7 million
potential cerebrovascular victims in this densely populated high-risk region [3].
Although most patients admitted with acute coronary
syndrome or acute ischemic stroke in South Asian countries receive these evidence-based treatments, their overall continuation in the outpatient phase of care remains
low. Patients from Pakistan are uniquely challenged in
this respect because the overall literacy rates remain one
of the lowest in Pakistan among South Asian countries.
In addition, a great majority of Pakistani patients often
do not understand or follow health prescriptions (which
are still written in English). Additionally, due to an unregulated health industry, patients frequently take
multiple opinions and prescriptions from different physicians [1, 4]. This lack of understanding leads to a reduced adherence to these often life-saving medications
and increases their risk for drug-drug interactions and
serious adverse reactions.
The purpose of this study is to develop and pilot
test a tailored health information technology-driven
intervention in Pakistani patients with coronary artery
disease (CAD) and ischemic strokes receiving care in
outpatient setting in the Aga Khan University Hospital
(AKUH) in Karachi, Pakistan. We hypothesize that this
health IT-driven intervention would address the abovementioned information gaps and will lead to an increase

in medication adherence. Furthermore, we hypothesize
that this health IT-driven intervention with improve
health literacy in this literacy-challenged, resource-poor
population.

Methods
Design overview

The Bolta Parcha (Talking Prescription; Talking Rx) trial
is a randomized, controlled, single center superiority
trial with blinded outcome assessment. (Fig. 1 – Study
flow chart) Adult participants, with access to a cell
phone and a history of vascular disease longer than
1 month of duration, who are taking multiple riskmodifying medications (inclusive of anti-platelets and
statins) will be selected from neurology and stroke
clinics at the AKUH.
They will be randomized into two parallel groups
(intervention group and control group) in a 1:1 ratio via
block technique. Both groups will have access to a helpline number to address their queries regarding their
illness and medications in addition to receiving the
standard of care as per institutional guidelines. In
addition, participants in the intervention group will also
have access to Interactive Voice Response (IVR)-based
informative voice messages tailored to their respective
prescriptions. The intervention group will also receive
daily tailored text messages regarding dosage and frequency of intake of statins and anti-platelet medications.
They would also receive weekly text message reminders
to improve medication adherence, lifestyle changes,
medication information, risk factors and motivation to
improve adherence. These messages are modeled on
Social Cognitive Theory and the Health Belief Model
and are categorized by Michie’s Taxonomy of Behavioral
Change Communication [5, 6].
Patients’ adherence to medications will be assessed
using the Morisky Medication Adherence Scale
(MMAS) [7]. In a sub-set of patients (20 % of patients
in each group), pill count will be performed to assess
the correlation between self-reported MMAS and
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Enrollment

Assessed for eligibility
Excluded (n = …)
Not meeting inclusion criteria
(n = …)
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(n = …)
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Analyzed (n = …)

Analyzed (n = …)

Excluded from analysis
(n = …)

Excluded from analysis
(n = …)

Fig. 1 Study flow chart. Standardized Consolidated Standards of Reporting Trials (CONSORT) flow for the Talking Prescription (Talking Rx) program

direct pill count. Patient’s health literacy will be measured at baseline and then after 3 months in each
group by using Likert’s Scale for Health Intelligence
Literacy, Knowledge of Medications, and a modified
version of Test of Health Literacy in Adults (TOFHLA)
(modified version) [8–10]. The difference in adherence to medication regimen (and health literacy) before and after the intervention will be compared between
the two groups to determine the effectiveness of our
intervention.

Study setting

The trial is being conducted in the cardiology and neurology clinics at the AKUH, Karachi, Pakistan. The center
is a Joint Commission International Accreditation (JCIA)
accredited tertiary care hospital located in Karachi, a large
metropolitan city located in the south of Pakistan. The
center also has logistic and technical expertise available
from dedicated research support staff and an independent
Clinical Trials Unit (CTU) and Aga Khan Development
Network e-Health Resource Center (AKDN eHRC).
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Participants

Participants attending neurology and cardiology clinics
at AKUH are recruited as study participants based on
the following criteria:
Inclusion criteria
 Age older than 18 years
 History of stroke(s) or CAD (MI, unstable angina, or









coronary intervention performed via percutaneous
coronary intervention or coronary artery bypass
grafting (CABG)) confirmed using objective
modalities at the time of the episode (i.e.,
neuroimaging, electrocardiogram (ECG), relevant
blood tests and physician examination and clinical
confirmation in medical records)
More than 1 month since last episode of stroke or
admission for CAD as described above
Use of anti-platelets and statins in addition to other
medications to control risk factors of cardiovascular
disease
Modified Rankin Score of 3 or less
Possession of a personal cell phone that the patient
has access to at all times. In the case of patients who
do not own, or are unable to use, mobile phones,
they must have a caregiver available at all times who
possesses a cell phone
Ability to receive, comprehend and reply to an SMS
in English or Urdu or Roman Urdu. In the case of
patients who themselves are unable to receive,
comprehend or reply to an SMS, they must have
caregivers available at all times who could perform
the above-mentioned tasks

In addition all participants are required to provide
a written, informed consent prior to enrollment.
Exclusion criteria
 Intention to travel within 3 months of recruitment
 History of current malignancy (diagnosed in the last

5 years and receiving treatment)
 Planned procedure (in the study time period of

3 months) which necessitates rapid medication
changes
Interventions
Intervention group

Talking Prescription (Bolta Parcha) At enrollment,
patients will be allotted unique identities (IDs). Patients in the intervention group will be given access
to an IVR which is specific to each patient in terms
of the medicines prescribed to that particular patient.
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(Fig. 2 – Interactive Voice Recording Menu) The physician’s prescription is transferred and scanned and
sent to the central program to customize the IVR
output for that particular participant. The intervention primarily focuses on two sets of medications (i.e.,
anti-platelets and statins) used in the treatment of
patients with stroke and with CAD. These two medication groups were chosen as they have been shown
to improve cardiovascular outcomes in patients with
stroke as well as those with CAD.
Patients in the intervention arm will be given a phone
number, which they can call on at any time of day or
night, where a voice recording will inform the patient
that the call is free of charge and they will now receive a
call back from AKUH. The patient will then receive a
call within a minute from AKUH where an IVR is being
played. A mandatory message is played explaining the
important instructions pertaining to all medicines. The
recording then lists medicines the patient has been prescribed serially and asks patients to choose to receive
information about either one medicine or all the medicines in their prescription. If, for example, the patient
chooses one medicine, the recording then lists the options available which the patient can choose from (dose,
frequency, how and when to take the medicine, drugdrug and drug-food interactions, side effects) and press
the assigned digit. The patient can listen to each subcategory serially, or targeted information as desired, once
or multiple times. This service is available free-of-cost
24 hours a day, 7 days a week.
This modality stresses the relevant pharmacodynamics
and pharmacokinetics explaining all the relevant information to the patient in an effort to maximize the effectiveness of this service. It focuses on educating the
patient on how and when to take the prescribed medication and about the necessary storage and usage instructions. It strives to impart detailed information regarding
the prescribed anti-platelets and statins to each patient
so that medication knowledge, adherence and proper
usage are highlighted. It also addresses the common
myths that surround medications in health literacychallenged areas – e.g., the myth that you can feel your
chronic disease, and therefore, if you feel better, you can
stop taking your medications.
Short Text Message Service (SMS) In addition to the
IVR service described above, the participant in the intervention arm will also receive an automated SMS which
is highly personalized, tailored to the medication prescription of that particular participant, with emphasis on
anti-platelets and statins. Daily automated medication
reminder SMS will be sent to all the participants to remind them to take their medicines. Using SMS, the
participants in the intervention arm will be asked if they
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Fig. 2 Interactive Voice Recording Menu. Interactive Voice Recording Work Flow (IVR) –the participant is able to “listen to” his medications and
how they work, their side effects and important interactions. All participants hear a mandatory recording that details essential information in
addition to detailed descriptions. There is no cost to this recording and they may listen to it as many times as they wish for clarity

have taken their anti-platelet/statin medication for
that day, and if not, then they will be urged to take
the medication then.
Furthermore, a SMS will be sent once weekly to each
patient in the intervention group which will reinforce
the importance of medication adherence, lifestyle modifications and cardiovascular risk factors. These aim to
boost medication adherence and health literacy. The
SMS are phrased using the behavior change intervention
taxonomy devised by Michie et al. [6].
Using the standardized definitions as presented in the
taxonomy allows for easy reproducibility and generalized
applicability for future work related to this intervention.
The specific content of the SMS is derived from the
Social Cognitive Theory and Health Belief Model of behavior change in health care [11, 12]. Templates used include “Pakistanis are at high risk of stroke and heart
attack. Please reduce your risk by taking your medicines
on time” and “Exercise is good for your health. Try to
perform regular exercise.” The purpose of adapting this

model for designing SMS is to make them effective in
communicating to the participants the consequences of
their behavior on health.
Please note that both IVR and SMS will be available in
English, Roman Urdu or Urdu based on patient preference. (Additional file 1 – SMS messages).
A hosted SMS gateway provided by our trial technical
support (eOcean) is used to send the SMS using web
services once upon uploading the medicine prescription
onto the application server and daily and weekly SMS
requested to the same server according to the participant’s prescription and profile [13].
Pill count On a select sub-set of the intervention group
(approximately 20 %) medication adherence will be
objectively monitored by doing a pill count. Selected patients are provided with two weekly pill organizers each
and their anti-platelets and statins are filled in these
organizers for 2 weeks. The patient is then asked to
return every 2 weeks for a pill count to objectively assess
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medication adherence as a direct measure of the intervention being provided to these patients via SMS and
Talking Prescription. These patients are required to visit
the facility for a pill count every 2 weeks until the cessation of the study (i.e., 3 months).
Control group

In the control group, patients will receive the usual
standard of care provided at AKUH for stroke/CAD patients. This primarily consists of regular follow-up visits
(frequency as per patient needs) with their stroke neurologist or cardiologist.
For index stroke patients, the standard schedule for
clinic visits after an uncomplicated recovery is 2 weeks,
1 month, 3 months and 6 months. On each clinic visit, a
detailed neurological examination is performed, stroke
risk factors are assessed and concerns and queries are
addressed. Each patient is provided with a telephone
number that can be used to reach the stroke team in
case of an emergency.
For index CAD patients especially those after a MI the
standard outpatient visit schedule after an uncomplicated
recovery is at 1 week, 1 month, 3 months and 6 months.
On each clinic visit, a detailed cardiovascular examination
is performed and CAD risk factors are assessed.
In both clinics, patients will be provided with a helpline number to which they can send a message if they
have any queries regarding their illness or medications.
These queries will be answered within the next 24 hours
by a physician.
In the control group, during clinics, patients are counseled regarding beneficial lifestyle practices and the significance of compliance with medication regimens. They are
also are offered reading materials about their disease in
English or Urdu. None of these activities, however, are extended beyond their clinic visit. Each patient also receives
clinic appointment reminders 1–2 days prior via SMS
and/or phone as per the center policy. The control group
does not receive any SMS for lifestyle management or an
IVR system that describes their medication prescription in
detail [14].
The reason for choosing this site and control group is
due to the standardization of care at this center and its
adherence to protocols. This assures that differences observed are due to the intervention itself and does not
allow overestimation of effect.
Technical detail: Talking Rx intervention

The system operates on the following two types of applications, which are integrated to each other:
1. Desktop-based imaging application: this is used for
scanning the prescription page, detecting markers of
medications, dose and frequency, and then translating
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it into an XML form which is understandable by the
web-based medical record application
2. Web-based medical record application: this is hosted
on a web-based server which registers patients,
keeps patients’ pharmacy data, translates XML into
record form and communicates with other messaging
servers through CSV file and HTTP protocols
In addition to the above-mentioned applications, the
system has a messaging and voice server. This server is
hosted at the service provider and contains an application
which stores all audio files in coded form. The application
accepts CSV file format from the web-based server and
binds specific audio files and messages based on the prescribed medicines with patients’ mobile phone numbers.
This server allows the web-based medical record to send
SMS to patients through HTTP protocols so that they can
call this server from their mobile phones to hear their
prescription.
Technical flow

The IVR flow of the intervention is as follows:
1. Patient registration: the patient is registered on
web-based application with his/her demographics,
history and mobile number
2. Acquisition: after receiving a scanned patient’s
prescription on an OMR sheet, a health
professional/receptionist/research assistant scans the
OMR sheet through a scanner using the web-based
application. This web-based application opens a
desktop-based application to scan the sheet, convert
it into an image and then translate it into XML format
3. Processing: upon scanning, the web-based application
obtains an XML file and translates it into patient
records on the basis of patient registration number.
After obtaining all the information, the web
application shows the medical drug status of
each patient so that the user can change status,
i.e., activate and deactivate a drug accordingly.
Upon confirmation of the request, the web-based
application sends a message to the messaging and
voice server which allocates patient-specific drugs
4. Messaging: upon registration or changing of a
prescription, a patient will receive SMS from the
messaging server along with an IVR short code to
call a specific number to hear their prescription,
within 4 hours
5. Voice response: as needed, patients can call the IVR
short code at any time and hear their prescription
details like frequency, indications, contraindications,
side effects, etc.
6. Periodic messaging: based on diseases and drugs,
the web-based system sends customized messages
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to patients through the messaging server periodically.
Through this feature, behavior change communication
is established to promote positive behavior in
patients
Outcomes: (Additional file 2 − Data Collection Form)

The primary outcome of interest is a change in medication adherence after 3 months of receiving the SMS and
being exposed to the Talking Prescription (Bolta Parcha).
Our secondary outcome is change in health literacy. The
findings of the treatment group on these outcomes will be
compared to the corresponding findings from the control
group to account for the Hawthorne effect.
Medication adherence will be measured at recruitment
and after 3 months in both groups using the MMAS.
The scale has been used in a similar setting previously
and it has been translated and validated in Urdu. The
change will be determined by comparing the score on
the MMAS before and after the intervention [15].
The instrument consists of eight questions and the response to each question is scored as either 0 (yes) or 1
(no). The maximum score, hence, is 8. A higher score
indicates better adherence. A score of less than 2 indicates low adherence.
The secondary outcome measure is assessment of
functional health literacy in adults (TOFHLA) which will
be assessed at enrollment and then at the follow-up visit
after 3 months. This tool has been adapted, modified,
and content-validated by a panel of experts, translated
and back-translated from English to Urdu, to better
represent the Pakistani community and its health system. It consists of two sections: the first section covers
questions about the basic instructions for each patient
coming to the clinic, and the second section contains
three passages comprised of questions about the relevant
information every patient visiting the hospital should
ideally possess.
Section 1 has a total of 17 questions, where a correct
answer merits a score of 1 and an incorrect answer gets
a score of 0. First Raw score is obtained after adding
responses to each question and this score out of 17 is
converted to a weighted score, using a reference table, to
a denominator of 50.
Section 2 has a total of 50 questions, where each
correct answer earns a score of 1 for the patient and an
incorrect answer earns a score of 0. The total score at
the end of this section is scored out of 50.
In the end, TOFHLA is evaluated on a total of 100,
where health literacy is given a total score ranging between
0 and 59 (inadequate), between 60 and 74 (marginal), and
from 75 up to 100 (adequate) [8].
In addition, we will perform sensitivity analyses
comparing the correlation between the MMAS and
the pill count.
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Study timeline

Prior to each stroke/cardiology clinic visit, potential
study participants will be identified from the clinic appointment lists. These patients, along with all other
walk-in patients, will be approached by research officers
during their visit to assess their eligibility for participation through an eligibility questionnaire. Those found
eligible are informed about the study and if willing, will
be requested to remain after their appointment for
recruitment and providing written, informed consent. If
a participant is interested but does not have time,
they will be offered information about the study and
asked to consider participation in the study at their
next clinic visit.
First, counseling is performed by a research officer, in
which details of the study, its purpose, objective, procedure and its follow-up visits are explained to the eligible
participant. Recruitment will begin with signing of an
informed consent and assigning the patient an ID number. Data collection will begin with a detailed interview
regarding the demographic and clinical details of the patient including his/her prescription details. The baseline
MMAS and TOFHLA scores for each patient will then
be assessed. This will be followed by the research staff
leaving the room and a senior investigator taking over, at
which point the patient will be randomized to either the
intervention or the control group by the CTU. The tasks
of allocation of intervention and randomization are carried out by the CTU staff (separate from the study staff )
and are independent from all studies that are ongoing at
the university site.
If the patient is allocated to the intervention arm, the
investigator will explain the details of the intervention.
The investigator will also demonstrates it by sending one
test SMS on his/her cell phone (in English and Urdu
both). Any questions pertaining to the use and comprehension of IVR or SMS will be answered at that point.
Patients in the intervention arm will then be provided
with a number on which they can dial (free-of-cost) the
Talking Prescription. The unblinded investigator will
then demonstrate this call to the participant and provide
orientation regarding proper use of this IT facility.
If there is a change in patient prescription with respect
to any drug or dose by any physician, the patient will be
requested to notify this on a helpline number that is
provided to them during enrollment. In addition, there
is a fortnightly review by a research officer to screen and
ensure safety and to draw attention to any prescription
change that has not been noticed. This allows the
Talking Prescription to be modified so that the patient can
then be sent instructions according to the new regimen.
The helpline is available round the clock and it could also
be reached in the case of any queries. The operator at
the helpline is trained to answer and deal with most
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frequently anticipated questions and queries and is given
access to a stroke neurologist and a cardiologist at all
times in case of queries beyond the scope of their knowledge. If it is anticipated that the participant will undergo
frequent medication changes, associated with, e.g.,
planned carotid endarterectomy (CEA), CABG, stent, etc.,
they are not enrolled into the program until their condition is stable.
Following the recruitment visit, the patients will not
be required to come back to clinic for any additional
visits except the end of the study visit at 3 months. The
only exception to this will be the select sub-set which is
selected for a pill count, which have a fortnightly review.
At the end of the study, patient adherence and health
literacy is assessed by the research officer who is unaware of patient allocation. (Fig. 3 − Participant timeline
for Talking Rx).
Duration

The trial will continue until we achieve our sample size
of 200 (100 in each arm). Follow-up for each study participant will be 3 months from the day of randomization.
Sample size

The sample size was calculated to detect a difference of
1 point on the primary outcome measure, MMAS, with
a power of 90 % and significance level of 5 % between
the two groups. The estimated sample size for the study
is 86 participants in each arm. Accounting for a 15 % attrition rate the minimum sample size required for the
study is 100 participants per arm, making a total of 200
participants to be randomized. The MMAS categorizes
low adherence as a score of <6, medium adherence as a
score of 6 to <8, and high adherence as a score of 8 [16].
Any 1-point shift is a clinically important increase in
scores. In addition, in a study carried out locally, we
have shown the use of IT-based interventions to have
effects on this score in these ranges [17, 18].
Assignment of interventions

Sealed opaque envelopes with patient assignments to either the intervention or the control group will be prepared by the CTU through a computerized block
randomization technique in block sizes of 10. This is to
ensure similarity between the two groups at all times,
permitting interim analysis during the study. Additionally this design block was not discussed with the research team interacting with participant recruitment.
The randomization numbers are sealed in opaque envelopes, marked by ID and kept with the CTU. Even if the envelope was held against bright sunlight, the allocation
would remain hidden. After enrollment, obtaining informed
consent and completing the baseline measurements, the
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CTU is informed and randomization of the participant is performed.
Data collection methods

The patients in both arms will be asked to attend after
3 months (90 days ± 15 days) for a follow-up interview to
assess adherence and health literacy. Data will be collected
on a data collection form (DCF) by a research officer who
is blinded to participant allocation. This primarily consists
of the MMAS and modified TOFHLA. In addition, in a
select sample of patients, the research officer will also perform pill counts every 2 weeks. (Additional file 2 − Data
Collection Form).
Participants in both arms will be reminded of their
appointment 2 days prior to the interview. Patients will
be compensated for travel to AKUH for the 3-month
follow-up visit. In case the participant does not report
for this appointment, they will be contacted again to
reschedule it.
Pilot testing

Pilot Testing was performed on 10 % of the sample size,
i.e., 20 patients before commencement of the study. As
per the actual study, participants were recruited from
neurology and cardiology clinics and standard procedures are followed. This allowed testing the intervention
for smooth application and any systematic errors. Problems with eligibility criteria were identified and the feasibility of achieving sample size was assessed. The data
collection tool was also assessed for flow of questions
and comprehensiveness. The intervention was assessed
for practicality relating to delivery, accuracy, timeliness,
comprehension and satisfaction. The participants in the
pilot testing are excluded from final study analysis.
Data management

Research officers are specifically trained to collect all
data during patient interviews leaving no data collection
forms incomplete. All data collected will be sent to the
research office in sealed envelopes. At the end of each
day any data missing from forms will be noted and asked
for. In case of missing data, the participant will be
contacted to fill the missing information. The data will
be entered by a separate team which will enter data on
EpiData. Data entry is depersonalized with study ID
assignment. This team does not include any members
involved with research. As per institutional policy,
double entry is mandatory for all data. The data entry
operators are blinded to the allocation of each patient.
All data entered is backed up centrally.
Statistical methods

Analysis will be performed using the intention-to-treat
principle: an interim analysis after 25 % of the sample has
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Fig. 3 Participant timeline. Timeline for Talking Prescriptions (Talking Rx) − participants are followed for 3 months. The intervention arm receives
Interactive Voice Recording (IVR) that improves prescription literacy and a short text message service (SMS) that cues medication adherence
behavior. The Pill Count Sub-study is at 2-week follow-up

Kamal et al. Trials (2016) 17:121

been reached and final analysis after data has been collected from all study participants. Since this is an IT-based
intervention, we plan to do an interim analysis to assess
technical compliance to intervention, any unexpected side
effects like participant fatigue and drop out. We do not
expect any serious safety issues to arise as this study only
concerns reception of educational intervention.
The use of the intention-to-treat principle for analysis
means that all patients will be analyzed in the treatment
arm to which they were randomized. Analysis will be
performed after the completion of follow-up of all study
participants. Protocol deviations and exclusions (with
reasons, will be reported for each arm of the trial). Estimates of intervention effects will be presented with 95 %
confidence intervals. A two-tailed P value of ≤0.05 will
be considered statistically significant for the outcome
measures.
For descriptive analysis, mean with standard deviation
or median with interquartile range will be reported for
continuous data. For categorical data, frequency with
percentages will be calculated.
The primary outcome analysis will be based on improvement in medication adherence level, assessed by
the change in MMAS score at 3 months of follow-up.
To report the difference between the mean scores of
intervention group and control arm, Student’s t test or
the Mann-Whitney U test will be performed.
To evaluate the secondary outcome, change in functional health literacy assessed by TOFHLA, the difference
of proportion between the two arms will be calculated
either by Pearson’s chi-square test or Fisher’s exact test.
To evaluate the correlation between adherence to
medications and pill counts either Pearson’s correlation
or the Spearman rank correlation test will be applied
and coefficients will be calculated to report the strength
of correlation.
All analysis will be performed on Stata version13.
Recruitment and retention plan

Patients in the hospital database with diagnoses of stroke
or MI are selected, following which their clinical histories are studied in detail to ascertain their eligibility criteria. If a participant is interested in the study, eligibility
is assessed during a telephone conversation only. If the
patient is found eligible, he or she is given the option of
visiting the research facility just for the enrollment interview or to coincide with the interview day with clinical
follow-up with the respective consultant at the hospital
(in case of an upcoming clinic appointment). In case of difficulty in visiting the facility, free pick up and drop off is offered to patients for the enrollment interview.
In order to retain participants the hotline number is
shared for all queries arising during enrollment and participants are thanked for their time during the study.
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Reminders are sent prior to interview dates and a 2week margin is given to allow a time suitable for CTU
visit. Due to telephone contact we will be able to collect
data on reasons for participant discontinuation, loss to
follow-up, etc.
Ethics and human subjects’ protection

All patients taking part in the trial will be required to
provide written informed consent at the time of recruitment after thorough counseling by the trial-trained
research associate, who is a research associate.
Consent forms have been approved by the Ethical
Review Committee (ERC) at AKUH and are available in
English and Urdu. The participants will have the right to
withdraw at any time during the study. In addition, their
inclusion or exclusion from the study will not affect the
usual standard care provided to them. Participants will
be financially reimbursed for all costs pertaining to their
follow-up visits. Participants identified as having depression and dementia will be referred to appropriate physicians for further management (see Additional file 3 –
Informed Consent Form).
In addition, special care is taken to maintain patient
confidentiality. Health promotional texts will be sent
once weekly at times that do not inconvenience the
patient such as late at night.
In days of high security alerts in the city and announced SMS blackouts, it is planned to send an
advanced SMS the night before to the participant so that
there would not be any SMS the next day, hopefully
avoiding participant anxiety or uncertainty about continuity of care or reception of services.
All team members have received Good Clinical Practice
(GCP) training and a face-to-face training, in a 2-day
neuroethics course regarding research in the developing world, where all design aspects for this trial were
discussed.
The protocol has been approved by the ERC of the Aga
Khan University. The study Ethical Review Number is
3165-MED-ERC_14. Any changes to the protocol will need
to be approved by the ERC before implementation and
reported to the trial registry at https://clinicaltrials.gov.
Six-monthly reviews on the progress of the trial will
be conducted by the ERC including inspection of signed
informed consent forms and the study will comply with
all ongoing audits for local regulatory compliance.
Access and dissemination policy

Only the collaborating principal investigators and research team will have access to the study results and
will be responsible for publishing them in a timely
manner. The funding source will not have any special
access or privileges regarding results before publication. The ERC will be given access to data if required.
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Results will be disseminated through scientific journals,
conferences and meetings.

Discussion
This study protocol presents the design of a randomized
controlled trial using Talking Prescriptions for improving
medication adherence and health literacy in patients
with stroke or CAD.
Technology has been used to increase medication adherence to HIV medications, polio vaccination, and most
asthma, hypertension and maternal and child care interventions in developed world populations [19–27]. In
general, SMS is the most common technology used for
these interventions. This is a patient-centered intervention which is friendly, repeatable and accessible and
requires no advanced literacy.
There are several unique aspects to this protocol. First,
technology has never been used in a unique high-risk
vascular disease population living in resource-strapped
settings with marginal support and poor health literacy
[28–31]. Second, the content used in this intervention
are not just simple knowledge transfer texts, the wording
and the content has been designed based on the Health
Belief Theory and Social Cognitive Model [32, 33].
Third, each behavioral communication message is informed by taxonomy and coded for easy replicability of
intervention [6]. Fourth, our study protocol, design and
methods are robust by the use of centralized
randomization, allocation concealment, blinded assessment, intention-to-treat analysis, and a design to ensure
maximum follow-up and minimize attrition [34–36].
The major limitation of this study is the choice of
measure of primary outcome, i.e., self-report of medication adherence on the Morisky Medication Adherence
Questionnaire [37, 38]. Although this tool has been validated in Urdu in the implementation country, using
assessment tools such as biochemical markers or electronic pill boxes may potentially provide more accurate
results. This however is not possible because of the complexity of a vascular patient’s prescription; this may
include drugs for multiple risk factors and multiple
drugs at the same time. Simply opening an electronic pill
box registers a dose as administered even if the patient
takes only two medicines out of the four he is prescribed
for that time, thus an electronic pill box could not
capture the data of a complicated regimen. Running biochemical tests for each of these medications would be
costly and impractical in a resource- constrained environment and would require repeat hospital visits [39–42].
In any arm, if the design required patients to make repeat visits during intervention and to interact with the
caregiver then the act of repeated interaction may then
be more responsible for adherence than the IT-based
intervention itself. However, we do intend to perform a

Page 11 of 13

limited pill count to add robustness and triangulation
data to our measures. Another limitation of our study is
that we are unable to blind participants to the educational intervention, so those on the intervention arm are
receiving SMS and are thus aware that they are on a
program to increase literacy and medication compliance.
A possible design to account for participant effect due to
the lack of blinding could be giving two versions within
the intervention where general information may be
imparted in one arm and more detailed specific intervention could be imparted to participants in the second
intervention arm as compared to the control. At this
pilot stage we were unable to plan for two versions in
this intervention arm since we were concerned about
how this technology would be received and used in this
early study.
Another limitation to the study is the application of
the literacy tool TOFHLA in a developing country like
Pakistan where the literacy rate varies between 28 and
96 %, varying sharply with age groups and regions. Since
Karachi is the largest metropolitan city of the country
with population of 9.3 million, literacy rate variations in
this city are expected. In addition, the health system in
Pakistan is very different to the US where this tool was
designed. Hence, TOFHLA was modified and adapted to
embrace the limitations encountered in our local community while we adhered to the basic architecture of
TOFHLA. First, section 1 was modified to encompass
our health system replacing insurance coverage with
topics more pertinent to our local health structure. Second, passages in section 2 were completely over-hauled
and replaced by our local data and advice by regional
content experts. In addition, each statement was kept
short and focused with just one blank to decrease the
confusion that was anticipated with the presence of
three to four blanks in the original version. The total
numbers of questions in each section were kept the
same to ensure accurate scoring as delineated in the
original tool. This modified TOFHLA was contentvalidated by five experts each, from the fields of neurology, cardiology and epidemiology/statistics. After
extensive fine-tuning, this tool was translated in Urdu
and thereby successfully tested in the pilot. Our Cumulative Validity Index (CVI) scores for the regionally
adapted TOFHLA were as follows: for relevance 0.87
and for clarity 0.72, which are excellent.
This study is regionally important. Pakistan, like other
emerging low- and middle-income countries, faces noncommunicable diseases like stroke and MI as its major
health challenge, so a low-cost intervention would have
a high impact [1, 4]. The study population is uniquely at
high risk and exceptionally vulnerable to these two
vascular diseases. Currently, the country has an electronic database with a unique identifier number, thus
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the potential of reaching masses as an extension is possible in addition to the already vast mobile infrastructure
[43]. Since most out-of-pocket, large, unanticipated expenditure on vascular disease would push most Pakistanis
into poverty, simple small steps in prevention would help
and, even if the expected effect size is modest, we may
ultimately have the potential to empower and positively
influence many more lives [44–46].
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